Neuromuscular disorders in systemic malignancy

Area of Science:

• Neurology
• Immunology
• Oncology

Background:

• Paraneoplastic neuronopathies are autoimmune disorders targeting neuronal proteins, with debated humoral and cell-mediated mechanisms.
• Neuromuscular manifestations in lymphoproliferative diseases challenge the distinction between neoplastic and paraneoplastic origins.
• Peripheral nerve toxicity from chemotherapy agents impedes cancer treatment advancements.

Purpose of the Study:

• To explore the autoimmune mechanisms underlying paraneoplastic neuronopathies.
• To investigate the causes and prevention of specific neurological syndromes like lower motor neuron syndrome and brachial plexopathy.
• To clarify the relationship between cancer and neurological disorders, including shared antigenic components.

Main Methods:

• Review of postulated humoral and cell-mediated autoimmune mechanisms.
• Analysis of radiation-induced lower motor neuron syndrome and brachial plexopathy.
• Application of polymerase chain reaction to differentiate neoplastic and paraneoplastic neuromuscular conditions.
• Investigation of shared antigenic components in paraneoplastic neuropathy and melanoma.

Main Results:

• Autoimmune attack on neuronal proteins is the presumed cause of paraneoplastic neuronopathies.
• Spinal column irradiation can cause proximal motor polyradiculopathy, leading to lower motor neuron syndrome.
• Lower radiotherapy doses and axillary surgery may prevent brachial plexopathy in breast cancer patients.
• Polymerase chain reaction challenges the clear distinction between neoplastic and paraneoplastic neuromuscular issues.
• Shared antigens may link inflammatory neuropathy and malignant melanoma.
• Chemotherapy toxicity to peripheral nerves limits treatment options for responsive tumors.

Conclusions:

• Paraneoplastic neuronopathies are complex autoimmune conditions with diverse clinical presentations.
• Understanding these mechanisms is crucial for developing targeted therapies and preventive strategies.
• Further research is needed to address chemotherapy-induced neurotoxicity and its impact on cancer patient outcomes.